From Early Development To Commercial Launch: An End-To-End Partnership For A Critical Therapy

Moving a critical therapy from early clinical development to commercial launch requires technical expertise, regulatory readiness, and careful coordination across every stage. For nearly eight years, Adare Pharma Solutions supported a breakthrough oncology therapy from Phase 1 clinical supply through FDA Fast Track review and commercialization.

The program presented complex challenges, including approximately 65% API loading, variability in API properties, evolving analytical requirements, and accelerated regulatory timelines. Adare adapted formulation and manufacturing processes while maintaining clinical supply, produced more than 35 clinical batches, and began commercial launch planning nearly a year before the FDA goal date.

That preparation translated directly into patient access: the first commercial product shipped within 8 days of NDA approval, and patients received therapy within 10 days. Discover how long-term CDMO collaboration can help navigate development complexity and prepare critical therapies for launch.